Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
The Board of Directors of Hofseth BioCare ASA ("HBC") has approved the financial statements for 2024, and HBC has today published the Annual Report and Sustainability Report for 2024. Please find the...
-
Hofseth BioCare ASA has retained Novum Asset Management AG to investigate the potential issuance of CHF-denominated unsecured bonds with an expected volume of up to CHF 8 million, towards investors in...
-
HBC will accelerate its manufacturing scale and market reach with the construction of a second enzymatic hydrolysis plant in Berkåk, Norway. Symrise will support the financing of the project through a...
-
Christoph Baldegger, primary insider and member of the Board of Directors in Hofseth BioCare ASA ("HBC") holds 1,500,000 shares personally and has held 1,747,976 shares indirectly through the Bonafide...
-
HBC achieved full-year sales revenue of NOK 256.8 million, a 35% increase from 2023, with strong momentum in higher-margin B2B human nutrition. The shift towards premium products, particularly CalGo®...
-
Christoph Baldegger, primary insider and member of the Board of Directors in Hofseth BioCare ASA ("HBC") has today purchased 700,000 shares in HBC at an average price of NOK 1.202837 per share. As a...
-
Hofseth BioCare ASA ("HBC" or the "Company", and together with its consolidated subsidiaries, the "Group") is pleased to announce a Board resolution to start a project to build a second hydrolysis...
-
HBC had gross operating revenues of NOK 67.9m (49.9m) in the third quarter and NOK 200.6m (171.1m) in the first nine months. The operating loss (EBITDA) for the quarter was NOK -21.0m (-16.2m) and NOK...
-
Christel Elise Kanli has decided to step down as Chief Financial Officer (CFO) of Hofseth BioCare ASA (“HBC”) to pursue opportunities outside of the company. "I would like to thank Christel for her...
-
Ålesund, Norway, 8 October 2024. HBC Immunology (HBCI) is pleased to announce the successful completion of its prostate cancer treatment xenograft studies with its lead peptide FT-002a in a novel...